Fig. 2: HPA-12 has synergistic effects when combined with Creno.

a, b Correlation of the CERT expression level with the sensitivity of AML cells to gilteritinib and sorafenib (TCGA). RPKM, per kilobase per million mapped reads. c, d Viability of Molm13 and MV4-11 cells treated with the CERT inhibitor HPA-12 or/and Creno. n = 3 independent experiments. e Combination index (CI) for Molm13 and MV4-11 cells treated with HPA-12 and Creno. The CI was calculated by Compusyn software. CI < 1, CI = 1, and CI > 1 indicate synergistic, additive, and antagonistic effects, respectively. Bliss synergy model displaying the viability of MOLM13 cells and MV4-11 cells (f) treated with HPA-12 and Creno. The cells were treated with the indicated concentrations of HPA-12 (0–100 µM) and Creno (0–8 µM), and cell viability was determined by the CCK-8 assay after 48 h. Treatment synergy was determined with the Synergy Finder website, and the Bliss synergy index is denoted as the red regions in the graphs. g, h Molm13 cells were treated with HPA-12 (80 µM) and Creno (6 µM), alone or in combination, for 48 h. The cells were subjected to an EdU assay (g, h) and annexin V/PI staining (i, j). g EdU-positive cells were identified by ImageJ. Scale bar, 50 μM. n = 3 independent experiments for (h) and (j). The data are presented as the means ± SDs, and differences were compared by 2-tailed Student’s t tests. Multiple groups were analyzed with one-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. The source data are provided as a source data file.